172 related articles for article (PubMed ID: 28947240)
1. Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin.
Lee EY; Gong EY; Shin JS; Moon JH; Shim HJ; Kim SM; Lee S; Jeong J; Gong JH; Kim MJ; Lee DH; Park YS; Shin J; Hong SW; Kim YS; Jin DH
Toxicol In Vitro; 2018 Feb; 46():229-236. PubMed ID: 28947240
[TBL] [Abstract][Full Text] [Related]
2. PMCA2 silencing potentiates MDA-MB-231 breast cancer cell death initiated with the Bcl-2 inhibitor ABT-263.
Curry M; Roberts-Thomson SJ; Monteith GR
Biochem Biophys Res Commun; 2016 Sep; 478(4):1792-7. PubMed ID: 27613092
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231.
Xu T; Liu P; Li Q; Shi C; Wang X
Taiwan J Obstet Gynecol; 2020 Nov; 59(6):828-834. PubMed ID: 33218396
[TBL] [Abstract][Full Text] [Related]
4. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway.
Huang KF; Zhang GD; Huang YQ; Diao Y
Int Immunopharmacol; 2012 Feb; 12(2):334-41. PubMed ID: 22182776
[TBL] [Abstract][Full Text] [Related]
5. Iron-free and iron-saturated bovine lactoferrin inhibit survivin expression and differentially modulate apoptosis in breast cancer.
Gibbons JA; Kanwar JR; Kanwar RK
BMC Cancer; 2015 May; 15():425. PubMed ID: 25998617
[TBL] [Abstract][Full Text] [Related]
6. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.
Tan N; Malek M; Zha J; Yue P; Kassees R; Berry L; Fairbrother WJ; Sampath D; Belmont LD
Clin Cancer Res; 2011 Mar; 17(6):1394-404. PubMed ID: 21220478
[TBL] [Abstract][Full Text] [Related]
7. Senolytic-Mediated Elimination of Head and Neck Tumor Cells Induced Into Senescence by Cisplatin.
Ahmadinejad F; Bos T; Hu B; Britt E; Koblinski J; Souers AJ; Leverson JD; Faber AC; Gewirtz DA; Harada H
Mol Pharmacol; 2022 Mar; 101(3):168-180. PubMed ID: 34907000
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression.
Kim YS; Jin HO; Seo SK; Woo SH; Choe TB; An S; Hong SI; Lee SJ; Lee KH; Park IC
Biochem Pharmacol; 2011 Aug; 82(3):216-26. PubMed ID: 21601561
[TBL] [Abstract][Full Text] [Related]
11. Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1.
Li G; Zhang S; Fang H; Yan B; Zhao Y; Feng L; Ma X; Ye X
Biochem Biophys Res Commun; 2013 May; 434(4):809-14. PubMed ID: 23611778
[TBL] [Abstract][Full Text] [Related]
12. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
[TBL] [Abstract][Full Text] [Related]
13. WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade.
Chuang YF; Huang SW; Hsu YF; Yu MC; Ou G; Huang WJ; Hsu MJ
Br J Pharmacol; 2017 Sep; 174(17):2941-2961. PubMed ID: 28646512
[TBL] [Abstract][Full Text] [Related]
14. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer.
Chen Q; Song S; Wei S; Liu B; Honjo S; Scott A; Jin J; Ma L; Zhu H; Skinner HD; Johnson RL; Ajani JA
Oncotarget; 2015 Sep; 6(28):25883-96. PubMed ID: 26317542
[TBL] [Abstract][Full Text] [Related]
15. Kinome-wide RNAi screening for mediators of ABT-199 resistance in breast cancer cells identifies Wee1 as a novel therapeutic target.
Aka Y; Karakas B; Acikbas U; Basaga H; Gul O; Kutuk O
Int J Biochem Cell Biol; 2021 Aug; 137():106028. PubMed ID: 34171479
[TBL] [Abstract][Full Text] [Related]
16. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
[TBL] [Abstract][Full Text] [Related]
17. Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263.
Polier G; Giaisi M; Köhler R; Müller WW; Lutz C; Buss EC; Krammer PH; Li-Weber M
Int J Cancer; 2015 Feb; 136(3):688-98. PubMed ID: 24895203
[TBL] [Abstract][Full Text] [Related]
18. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
20. HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression.
Witzens-Harig M; Giaisi M; Köhler R; Krammer PH; Li-Weber M
Int J Cancer; 2016 Jan; 138(2):507-14. PubMed ID: 26260669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]